▲ Among the participating firms are AztraZeneca, Bayer, Sanofi Pasteur, Roche, Pfizer, Novartis, Novo Nordisk and Boehringer.Photo Marco Peláez
Laura Poy Solano
La Jornada Newspaper
Saturday, December 28, 2024, p. 8
Biological and Reactive Laboratories of Mexico (Birmex) reported that 400 companies submitted proposals to participate in the international public tender LA-12-NEF-012NEF001-1-1-2025, for the consolidated purchase of medicines, therapeutic goods, healing materials and diagnostic assistants for fiscal years 2025-2026.
In the minutes of presentation and opening of proposals, issued on December 26, Birmex clarified that one of the participating companies, the company Productos Hospitalarios de Occidente, SA de CV –specialized in the manufacturing of healing materials– is sanctioned by the Ministry of the Public Service (SFP) so your proposals will not be received.
It indicates that in a review by the director of suppliers and contractors sanctioned by the SFP, it was detected that the aforementioned company violated the Law on Acquisitions, Leasing and Public Sector Services by not signing a purchase order for the amount of 71 thousand 2 pesos
which generated a fine of 25 thousand pesos, imposed by the internal control body of the Secretariat of National Defense, for which Birmex abstains from receiving his proposal
.
The document informs that the subsequent offer of discounts will be made this January 1 and 2, through the government purchasing platform Compranet, and the ruling will be announced on January 4, from which with 15 calendar days for signing the contracts.
Among the companies that presented the legal and administrative documentation to participate in the tender, as well as their economic and technical proposals, include laboratories such as AztraZeneca, Bayer de México, Sanofi Pasteur, Roche de México, Pfizer, Novo Nordisk México, Novartis Farmacéutica and Boehringer Ingel-helm Mexico, among others.
26 public health institutions participate in this type of consolidated purchase of medicines for 2025 and 2026. It is estimated that up to 152,043 million pesos can be invested to acquire the 3,900 keys requested by the institutions, 1,358 correspond to medications and 2,540 to medical devices.
To achieve this goal, there is a mechanism for the subsequent offer of discounts (reverse auction), with which the federal administration seeks to obtain the lowest possible price for medicines, by creating competition between participating pharmaceutical laboratories.
